Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Pancreatic Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


10 drugs have received FDA approval for Pancreatic Cancer . /LU, Erlotinib Hydrochloride, Everolimus, Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Lanreotide Acetate, Mitomycin, Paclitaxel and Sunitinib Malate
293 drugs have a clinical trial registered for Pancreatic Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 1732 clinical trials for Pancreatic Cancer,
1048 of which have one or more drug interventions,
684 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 318 Cell Line Models for Pancreatic Cancer.

Source: COSMIC
(see details)

Chemistry


There are 2330 Compounds which have been tested in Pancreatic Cancer , 1635 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Pancreatic Cancer:
Carcinoma, Pancreatic Ductal
Pancreatic Intraductal Neoplasms
Pancreatic Neoplasms

The following terms have been mapped from cancer.gov to Pancreatic Cancer:
Gastric (stomach) and pancreatic adenocarcinoma that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other types of treatment
Gastroenteropancreatic neuroendocrine tumors. It is used in adult patients whose cancer is somatostatin receptor positive.
Gastroenteropancreatic neuroendocrine tumors. It is used in some patients whose tumors cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body)
Pancreatic cancer
Pancreatic cancer that has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with gemcitabine hydrochloride
Pancreatic cancer that has metastasized. It is used with gemcitabine hydrochloride
Pancreatic cancer that is advanced or has metastasized. It is used in patients whose disease cannot be removed by surgery and who have already been treated with other chemotherapy. It is used with paclitaxel albumin-stabilized nanoparticle formulation
Pancreatic cancer, gastrointestinal cancer, and lung cancer (certain types). It is used in adults with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body)
Pancreatic cancer. It is used in patients with progressive neuroendocrine tumors that cannot be removed by surgery, are locally advanced, or have metastasized (spread to other parts of the body)
Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery, is locally advanced, or has metastasized